Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce new data from two Phase 1 studies in healthy volunteers in the United States of America, which evaluated long-acting BRII-732 and BRII-778, both are drug candidates in development for the treatment of human immunodeficiency virus ("**HIV**") infection. Results from both studies show that once-weekly dosing of BRII-732 and BRII-778 are safe and well-tolerated, generating important data to support the ongoing development of a potential first-in-class once-weekly oral combination therapy to treat HIV. The findings from these studies were presented in two poster sessions at Infectious Disease Week ("**IDWeek**") 2022.

One of the posters presented at IDWeek 2022 titled, *Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects*, highlights that oral BRII-732 demonstrated an acceptable safety and tolerability profile following a single ascending dose ("**SAD**") up to 200 mg and multiple ascending doses ("**MAD**") up to 25 mg, as well as a favorable and linear pharmacokinetic ("**PK**") profile that achieved therapeutic targets. These data reinforce potential development of BRII-732 as part of a combination antiretroviral therapy, inclusive of once-weekly dosing.

"Our HIV research program aims to advance the standard of care for more than 38 million people living with HIV around the world, many of whom desire new treatment options that enable a more convenient administration while also helping them to manage this lifelong infection," said Dr. Ji Ma, Ph.D., Vice President of Preclinical Development and Clinical Pharmacology at the Company. "These findings illustrate the potential for BRII-732 and BRII-778 to become a safe, well-tolerated and novel treatment regimen for patients that may help to ease the burden of daily medications and even minimize the social stigma that many people living with HIV are currently facing. We look forward to progressing the clinical development of both compounds, BRII-732 and BRII-778, into the next stage of studies as we work to advance a first-of-its-kind investigational oral long-acting combination treatment option for patients."

A second poster at IDWeek 2022 titled, *Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects*, demonstrates that SAD and MAD administration of BRII-778 formulations are generally safe and well-tolerated with PK profiles consistent with slower oral absorption, providing key insights for ongoing clinical evaluation and development of BRII-778 as part of a potential once-weekly regimen for the treatment of HIV.

In addition, three of the Company's strategic development partners presented a total of 16 abstracts related to assets under co-development with the Company at IDWeek 2022. This collective presence at IDWeek 2022 underpins the robust scientific progress across the Company's anti-infectives portfolio designed to tackle a broad range of infectious diseases that present significant public health burdens to people around the world. As part of these partnerships, the Company holds the licensing rights to advance multiple therapeutic candidates in the Greater China for multi-drug resistant ("**MDR**") and extensive drug resistant ("**XDR**") gram-negative infections with Qpex Biopharma, Inc., as well as non-tuberculosis mycobacteria with AN2 Therapeutics, Inc.

"This robust set of data from the Company's HIV program as well as our partnered assets in MDR/XDR antibiotics not only highlight the Company's expertise and leadership across the infectious disease area, but also demonstrate our commitment to develop unique therapeutic solutions for diseases that present significant, and in some cases rapidly growing, medical needs for patients and healthcare providers alike," said Dr. David Margolis, M.D., MPH, Head of Infectious Diseases Therapy Area at the Company. "As we continue our work to bridge the gap between scientific breakthroughs and patients' needs, we are committed to innovate new therapeutic candidates for some of the world's most common illnesses, including HIV, where current oral treatment options are limited to life-long daily dosing, which is considered problematic and disruptive to daily life by many people living with HIV."

The posters presented at IDWeek 2022 can be accessed online by registered attendees via the interactive program site.

Cautionary Statement: There is no assurance that BRII-732 or BRII-778 will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, October 19, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.